These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16574997)

  • 1. Developing a new framework for dose calculation.
    Gurney H
    J Clin Oncol; 2006 Apr; 24(10):1489-90. PubMed ID: 16574997
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
    Loos WJ; de Jongh FE; Sparreboom A; de Wit R; van Boven-van Zomeren DM; Stoter G; Nooter K; Verweij J
    J Clin Oncol; 2006 Apr; 24(10):1499-506. PubMed ID: 16574999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Getting the right dose in cancer chemotherapy--time to stop using surface area?
    Newell DR
    Br J Cancer; 2002 Apr; 86(8):1207-8. PubMed ID: 11953873
    [No Abstract]   [Full Text] [Related]  

  • 4. A flat dose for all adult [sic] patients.
    Bleyer WA
    J Clin Oncol; 1998 Nov; 16(11):3715. PubMed ID: 9817295
    [No Abstract]   [Full Text] [Related]  

  • 5. Medication errors. Cisplatin death.
    Cohen MR
    Nursing; 1998 Feb; 28(2):18. PubMed ID: 9496075
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
    Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
    Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin.
    Moreno D; Zalba S; Colom H; Trocóniz IF; Tros de Ilarduya C; Garrido MJ
    Eur J Pharm Sci; 2009 Jun; 37(3-4):341-50. PubMed ID: 19491025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BSA-based dosing and alternative approaches.
    Sparreboom A
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):448-50. PubMed ID: 16167020
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of low-dose daily cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy.
    Jeremić B; Milicić B
    Radiother Oncol; 2008 May; 87(2):201-3. PubMed ID: 18207598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular events in survivors of high-dose chemotherapy for germ cell tumors.
    Ishioka J; Fujii Y; Kageyama Y; Fukuda H; Higashi Y; Kihara K
    Int J Urol; 2008 Jul; 15(7):642-5. PubMed ID: 18643784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of intraarterial high-dose cisplatin with concomitant irradiation on arterial microanastomosis: an experimental study.
    Wang ZH; Zhang SZ; Zhang ZY; Zhang CP; Hu HS; Kirwan J; Mendenhall WM
    Am J Clin Oncol; 2009 Apr; 32(2):158-62. PubMed ID: 19307956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of fixed dosing of new anticancer agents in phase I studies.
    Levêque D
    Anticancer Res; 2008; 28(5B):3075-7. PubMed ID: 19031959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lower costs for anticancer drugs by safety margin around calculated dose and by fine-tuning on ampoule strength].
    Mertens S; de Jongh FE
    Ned Tijdschr Geneeskd; 2009; 153():B162. PubMed ID: 19785801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Individual therapy in oncology].
    Jaehde U
    Med Monatsschr Pharm; 2003 May; 26(5):155-8. PubMed ID: 12784504
    [No Abstract]   [Full Text] [Related]  

  • 15. Percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma.
    Maruo T; Motoyama S; Hamana S; Yoshida S; Ohara N; Yamasaki M; Ku Y
    Surg Oncol Clin N Am; 2008 Oct; 17(4):843-56, x. PubMed ID: 18722922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen.
    Arora R; Thakur JS; Azad RK; Mohindroo NK; Sharma DR; Seam RK
    Indian J Cancer; 2009; 46(4):311-7. PubMed ID: 19749461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of low-dose cisplatin-based chemo-irradiation in assessing hearing loss for locally advanced head and neck cancer.
    Liao XB; Yan SX
    Radiother Oncol; 2009 Feb; 90(2):282, author reply 282-3. PubMed ID: 19042049
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
    Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible cell-specific drug delivery with aptamer-functionalized liposomes.
    Cao Z; Tong R; Mishra A; Xu W; Wong GC; Cheng J; Lu Y
    Angew Chem Int Ed Engl; 2009; 48(35):6494-8. PubMed ID: 19623590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.